Ontario invests US$15m in state-of-the-art newborn screening programme
This article was originally published in Clinica
Ontario will invest Can$18m (US$15m) to develop what will be the most comprehensive newborn screening programme in the country. Can$5m will be spent on one-time equipment purchases, followed by Can$13m in ongoing, annual funding. The hospital chosen as the site for the state-of-the-art programme is the Children's Hospital of Eastern Ontario. Facilities and procedures available will include: three tandem mass spectrometry machines to screen for inherited metabolic disorders (IMD); screening for blood and endocrine disorders (26 tests) using additional technologies, such as automated enzyme assays, immunoassays, high-pressure liquid chromatography and/or electrophoresis.
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.